Therapeutic virotyping for antiviral combination design

Virus taxonomy and the Baltimore system organise viruses by evolution and genome expression. We propose hierarchical therapeutic virotyping based on the materials produced during infection. First level assigns a composition virotype (nucleic-acid-only replicators; non-enveloped; enveloped). Second level maps these to three therapeutic material layers: N (nucleic-acid processes), P (protein processes) and L (lipid/membrane processes). Third level resolves the layers into a core scaffold (N1–N8, P1–P8, L1–L8) plus context-dependent extensions. Modifier enzymes are assigned by therapeutic endpoint; host responses remain an optional annotation. The resulting N/P/L dependency fingerprint supplies a structured feature space for combination prioritisation. Candidate combinations advance through claim-specific evidence gates from molecule to clinical evaluation. Therapeutic virotyping therefore links composition, functional dependency and experimentally testable combination design.